CODEL: Phase III study of RT alone, RT plus temozolomide, or temozolomide alone for newly diagnosed 1P/19Q codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design (NCCTG N0577, Alliance)
- Citation:
- Neuro-oncology vol 22 (2) NP CTNI-29.
- Meeting Instance:
- SNO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Other
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2880
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, UG1CA233320, UG1CA233329, UG1CA232760; U10CA180820 (ECOG-ACRIN); U10CA180863 (CCTG); U10CA180868 (NRG)
- Corr. Author:
- Authors:
- Kurt A. Jaeckle Karla V. Ballman Martin van den Bent Caterina Giannini Evanthia Galanis Paul D. Brown Robert B. Jenkins J Gregory Cairncross Wolfgang Wick Michael Weller Kenneth D. Aldape Jesse G. Dixon S. Keith Anderson Jane H. Cerhan Jeffrey S. Wefel Martin Klein Stuart A. Grossman David Schiff Frederick Dhermain Donald G. Nordstrom Patrick J. Flynn Michael A. Vogelbaum
- Networks:
- CA011, FL065, IA085, LAPS-MN026, LAPS-TX035, MN017, MN022, OH027, VA009
- Study
- NCCTG-N0577
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: